1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS 22990-19-8 Assay ≥98.5% (HPLC) Factory

Name: 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline   CAS: 22990-19-8 Appearance: White Crystal Powder Assay: ≥98.5% (HPLC) Assay: 98.5%~101.0% (on the dried basis) Intermediate of API (CAS: 242478-38-2) in the treatment of Overactive Bladder (Pollakiuria) Enquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light & moistureCommercial Supply Related Intermediates:  CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8
Item Specifications
Appearance White Crystal Powder
Single Impurity ≤0.20%
Melting Point 93.0~99.0℃
Loss on Drying ≤0.50%
Assay ≥98.5% (HPLC)
Assay 98.5%~101.0% (on the dried basis)
Test Standard Enterprise Standard
Usage (CAS: 242478-38-2) Intermediate

Description:

Specifications:

Package & Storage:

Chemical Name 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline
Synonyms 1,2,3,4-Tetrahydro-1-Phenylisoquinoline
CAS Number 22990-19-8
CAT Number RF-PI155
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C15H15N
Molecular Weight 209.29
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

API (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. The synthesis of (CAS: 242478-38-2) involves the preparation of racemic 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-Quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline may be subjected to optical resolution with (+)-Tartaric Acid prior to treatment with ethyl chloroformate and subsequent transesterification. 

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours